1. Novikov P.V. Legal issues relating to rare (orphan) diseases – russian and international experience. Medicine. 2013; 4: 53-73 (in Russian)
2. Novikov P.V., Semyachkina A.N., Voinova V.Yu., et al. Federal clinical recommendations on diagnosis and treatment of mucopolysaccharidosis IV. Moscow; 2013: 22 (in Russian)
3. Harmatz P., Giugliani R., Schwartz I. et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a Phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human Nacetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J. Pediatr. 2006; 148: 533-9.
4. Pisaryuk A.S., Lazarev P.V., Lobzhanidze T.V., Shavarov A.A. Mucopolysaccharidosis VI: multiple visceral involvement and the treatment with Naglazyme. Klinicheskaya farmakologiya i terapiya. 2014; 23 (3): 76- 81 (in Russian)
5. Mikhailova L.K., Nechvolodova O.L., Kolesov S.V., et al. Study of mucopolysaccharidosis at CITO. In: Proc. All-Rus. Scient. Pract. Conf. “Priorov’s readings” and Conf. Young Scientists. Moscow, 2015: 110-3 (in Russian)